MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan

MHRA-101897-PIP01-25

Scope of the Application

Active Substance(s)

doxecitine; doxribtimine

Condition(s)

Treatment of thymidine kinase 2 deficiency

Pharmaceutical Form(s)

Powder for oral solution

Route(s) of Administration

ORAL USE; GASTRIC USE

Name / Corporate name of the PIP applicant

UCB Pharma Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, UCB Pharma Limited submitted to the licensing authority on 17/04/2025 08:31 BST an application for a Paediatric Investigation Plan

The procedure started on 06/05/2025 07:59 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101897-PIP01-25

Of 04/06/2025 17:31 BST

On the adopted decision for doxecitine; doxribtimine (MHRA-101897-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for doxecitine; doxribtimine, Powder for oral solution , ORAL USE GASTRIC USE .

This decision is addressed to UCB Pharma Limited, 208 Bath Road, Slough, UNITED KINGDOM, SL1 3WE

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of thymidine kinase 2 deficiency

2.2 Indication(s) targeted by the PIP:

Treatment of thymidine kinase 2 deficiency with onset of symptoms on or before 12 years of age.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Powder for oral solution

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	1	Study 1 (MT1621-19-008) Definitive juvenile toxicity rat study to evaluate the toxicity and toxicokinetic characteristics of pyrimidine nucleosides doxecitine /doxribtimine.
Clinical Studies	3	Study 2 (MT-1621-101) Retrospective chart review study to evaluate the efficacy and safety of the combination of pyrimidine nucleosides in children from birth to less than 18 years of age (and adults) with thymidine kinase 2 (TK2) deficiency. Study 3 (TK0102 [previously MT-1621-102]) Open-label study to evaluate the efficacy, safety and pharmacokinetics of doxecitine / doxribtimine in children from birth to less than 18 years of age (and adults) with thymidine kinase 2 (TK2) deficiency. Study 4 (MT-1621-107) Retrospective chart review study to evaluate and complement efficacy and safety data of the combination of pyrimidine nucleosides in children from birth to less than 18 years of age (and adults) with thymidine kinase 2 (TK2) deficiency not treated or treated with pyrimidine nucleoside therapy.
Extrapolation, Modeling & Simulation Studies	1	Study 5 Population pharmacokinetic modelling study and exposure-response analysis to define and confirm the dose of doxecitine / doxribtimine to be used in children from birth to less than 18 years of

		age with thymidine kinase 2 (TK2) deficiency.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2025
Deferral of one or more studies contained in the paediatric investigation plan:	No